EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment Outcomes

D Magalhaes, M Santiago, M Patita, B Arroja, P Lago, I Rosa iD, H T Sousa iD, P Ministro, I Mocanu, A Vieira, J Castela, J Moleiro und 12 weitere

United European Gastroenterology Journal · 2025

DOI: 10.1002/ueg2.12712 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von D Magalhaes und 23 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Biomedicine, Unit of Pharmacology and Therapeutics, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Infliximab, Crohn Disease, Neutrophils, Gastrointestinal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Grupo de Estudo da Doença Inflamatória Intestinal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Predicting the treatment outcomes of biological therapies is an unmet need in Crohn's Disease. In this study, we explored the potential of serum neutrophil‐related biomarkers to predict infliximab therapeutic results and disease progression in Crohn's Disease patients, over a 2‐year period, in a real‐world setting.

Methods

The study included 100 asymptomatic Crohn's Disease patients in the IFX maintenance phase from the prospective, observational, multicenter DIRECT study. Patients were categorized according to a composite outcome reflecting progression that included surgery, hospitalizations, new fistulae, abscess or stricture, and drug treatment escalation. Serum neutrophil elastase, lipocalin‐2, lactoferrin, and resistin (non‐neutrophil control) were analyzed via multiplex magnetic bead assays at multiple touchpoints. Fecal calprotectin was assessed by ELISA.

Results

Over up to 2 years of follow‐up, serum biomarkers did not differentiate between the composite outcome groups, whereas fecal calprotectin was significantly higher in patients with worse outcomes. During the infliximab maintenance phase, there was a significant, sustained reduction of neutrophil elastase ( p < 0.001), lipocalin‐2 ( p < 0.001), and lactoferrin ( p < 0.001), but not of resistin, despite stable neutrophil levels. Correlations between NE and NGAL levels were strong (Pearson correlations 0.75–0.85); all other correlations were of small magnitude.

Conclusion

Our real‐world data do not support using serum neutrophil elastase, lipocalin‐2, or lactoferrin concentrations as predictors of treatment outcomes or disease evolution in infliximab ‐treated Crohn's Disease patients. On the other hand, the sustained decrease in biomarkers over time suggests that neutrophil stabilization might be an additional infliximab mechanism of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabCrohn DiseaseNeutrophilsGastrointestinal AgentsHumansFemaleMaleBiomarkersLeukocyte L1 Antigen ComplexAdultLipocalin-2Disease ProgressionFecesLactoferrinProspective StudiesLeukocyte ElastaseTreatment OutcomeMiddle AgedResistinYoung AdultFollow-Up Studies

Stichwörter der Autor:innen

Crohn's diseasefecal calprotectininfliximablactoferrin’lipocalin‐2neutrophil elastaseresistinserum neutrophil biomarkers

Substanzen

InfliximabBiomarkersLeukocyte L1 Antigen ComplexLipocalin-2LactoferrinLeukocyte ElastaseLCN2 protein, humanGastrointestinal AgentsResistinRETN protein, human

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Biomedicine, Unit of Pharmacology and Therapeutics, University of Porto, Porto, Portugal.
  • CINTESIS (Center for Health Technology and Services Research), Porto, Portugal.
  • GEDII (Portuguese Inflammatory Bowel Disease Group), Porto, Portugal.
  • Department of Gastroenterology, Garcia da Orta Hospital, Almada, Portugal.
  • Department of Gastroenterology, Braga Hospital, Braga, Portugal.
  • Department of Gastroenterology, Porto Hospital University Centre, Porto, Portugal.

ORCID-Profile: I Rosa, H T Sousa, J Roseira, P Sousa, S Danese, L Peyrin-Biroulet

Förderung

  • Grupo de Estudo da Doença Inflamatória Intestinal

Zitieren

APA

Magalhaes, D., Santiago, M., Patita, M., Arroja, B., Lago, P., Rosa, I., Sousa, H. T., Ministro, P., Mocanu, I., Vieira, A., Castela, J., Moleiro, J., Roseira, J., Eugenia, C., Sousa, P., Portela, F., Correia, L., Dias, S., Afonso, J., …, & GEDII (2025). Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment Outcomes. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12712

Vancouver

Magalhaes D, Santiago M, Patita M, Arroja B, Lago P, Rosa I, et al. Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment Outcomes. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12712

BibTeX
@article{Magalhaes2025,
  author = {Magalhaes, D and Santiago, M and Patita, M and Arroja, B and Lago, P and Rosa, I and Sousa, H T and Ministro, P and Mocanu, I and Vieira, A and Castela, J and Moleiro, J and Roseira, J and Eugenia, C and Sousa, P and Portela, F and Correia, L and Dias, S and Afonso, J and Danese, S and Peyrin-Biroulet, L and Dias, C C and Magro, F and GEDII, GEDII},
  title = {Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment Outcomes},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  doi = {10.1002/ueg2.12712}
}
Kostenlos starten →